• ABOUT
  • ADVERTISE
  • PRIVACY POLICY
  • TERMS OF USE
  • CAREERS
  • CONTACT
Monday, January 25, 2021
Subscribe to Newsletter
No Result
View All Result
Whistleblower Network News
  • Home
  • News
    • Corporate
    • Dodd-Frank
    • False Claims-Qui Tam
    • Foreign Corruption
    • Government
    • Intelligence
    • IRS & Tax
    • Legislation
    • OSHA
    • Sarbanes-Oxley
    • SEC
  • Editorial
  • Opinion
  • Whistleblower of the Week
Whistleblower Network News
  • Home
  • News
    • Corporate
    • Dodd-Frank
    • False Claims-Qui Tam
    • Foreign Corruption
    • Government
    • Intelligence
    • IRS & Tax
    • Legislation
    • OSHA
    • Sarbanes-Oxley
    • SEC
  • Editorial
  • Opinion
  • Whistleblower of the Week
No Result
View All Result
Whistleblower Network News
No Result
View All Result
Home Breaking News

Whistleblowers in Novartis Bribery Scandal Receive European Award

Mark WorthbyMark Worth
October 28, 2020
in Breaking News, Features, Global Whistleblowers
Reading Time: 3min read
0
Novartis whistleblowers
Share on TwitterShare on FacebookShare on LinkedInEmail

Scandal and corruption have followed Novartis non-stop along the entire arc of its 50-year history. Just a year after its corporate predecessor Ciba-Geigy was founded in 1970, the company’s dysentery drug clioquinol was pulled after it was linked to brain damage, blindness and other serious health problems in Japan. 

Since then, Novartis’ rap sheet has been filled with episodes of many other harmful drugs, antitrust charges, bid-rigging, price-fixing, Medicare misconduct, toxic pollution, illegal advertising, pay-to-prescribe schemes, kickbacks and bribery. Notwithstanding Novartis’ many legitimate contributions to alleviating illness and disease, the company’s long history of misconduct is shocking and saddening. These misdeeds were not committed by a socially detached bank or hedge fund, but by a company committed to preserving and improving the health of people.

In recognition of exposing Novartis’ latest bribery and corruption scandal, whistleblowers in Greece have received a prominent award from European lawmakers. Last month these citizens received the “Journalists, Whistleblowers and Defenders of the Right to Information Prize.” Dedicated to the memory and legacy of murdered Maltese journalist Daphne Caruana Galizia, the award is presented annually by the European United Left/Nordic Green Left faction of the European Parliament.

Among the confidential and anonymous whistleblowers are those represented by Stephen M. Kohn of the US-based whistleblower law firm Kohn, Kohn & Colapinto.

These bombshell disclosures led directly to $347 million in fines imposed on Novartis in June by the US Securities and Exchange Commission and Department of Justice. The penalties, which include disgorgement of $92 million in ill-gotten revenue, also cover offenses committed by Novartis and affiliates in South Korea and Vietnam.

According to the SEC and DOJ, Novartis and its former subsidiary Alcon gave improper payments and other benefits to healthcare providers in exchange for using and prescribing the companies’ medical products. Those receiving the corrupt payments included employees of publicly owned hospitals and clinics. Novartis brand managers and sales managers in Greece instructed subordinate staffers on how to distribute these “investments,” which were improperly recorded in the company’s books as advertising, marketing and sales expenses.

Also, in Greece, Novartis paid $5,000 to health care providers they considered to be “key opinion leaders” to attend events, according to the SEC and DOJ. In exchange they agreed to prescribe Novartis’ macular degeneration drug Lucentis. Novartis recorded the arrangements as a return on investment. Novartis monitored the providers’ performance and reduced or stopped the illicit payments to those who did not meet their quotas.

One week after these fines were announced, the US Department of Justice fined Novartis $642 million for Medicare-related misconduct and paying kickbacks to doctors and other medical professionals to promote its drugs. The scheme was exposed by former Novartis sales representative Oswald Bilotta.

It remains to be seen whether nearly $1 billion in penalties levied within the span of seven days – along with negative publicity and a drop in stock price – will persuade Novartis to change its ways. What is certain is that company insiders will continue to become aware of any crimes being committed by Novartis, and that there are willing eyes and ears in the media, whistleblower law firms, and law enforcement agencies that are eager to receive and act on the evidence.

Protect Yourself: Purchase the New Whistleblower Handbook Protect Yourself: Purchase the New Whistleblower Handbook Protect Yourself: Purchase the New Whistleblower Handbook
Tags: NovartisOswald BilottaStephen M. Kohn
Mark Worth

Mark Worth

Mark Worth is a whistleblower advocate, investigative journalist, public interest activist, author, and publisher. He is the Executive Director of the European Center for Whistleblower Rights and is the founder of many organizations, campaigns, and publications. Mark is the Co-recipient of the 1994 Investigative Reporters and Editors Award for best magazine article.

Write a Letter to The Editor.

Most Popular

Grenfell Tower Fire Whistleblowers Caught in Legal Limbo

Yellen Dodges Senate Whistleblower Question

Who Is Rebekah Jones? Profile on Florida COVID-19 Data Scientist

IUCN Motions Essential In Guiding New International Whistleblower Law, Environmental Whistleblower Policy Expert Explains

Allison Lee Appointed Acting Chair of SEC

Whistleblower Complaint Leads to SEC Investigation of Exxon

Whistleblower Poll

Increased Whistleblower Protections
Legislation

Candidate’s Position on Increased Whistleblower Protections Influences 44% of Likely Voters

byAna Popovich
October 6, 2020
0

Protect Yourself: Buy the New Whistleblower Handbook Protect Yourself: Buy the New Whistleblower Handbook Protect Yourself: Buy the New Whistleblower Handbook

STAY INFORMED. Sign up for daily whistleblower email and social notifications from the Whistleblower Network News.

  • This field is for validation purposes and should be left unchanged.

Qui Tam

  • Dodd-Frank
  • IRS & Tax
  • SEC
  • Foreign Corruption
  • False Claims-Qui Tam

Retaliation

  • OSHA
  • Sarbanes-Oxley

Government

  • Government
  • Intelligence
  • Legislation
  • Veterans

Features

  • Whistleblower of the Week
  • Editorial
  • Features
  • Interviews
  • Opinion

Resources

  • FAQs
  • National Whistleblower Day
  • National Whistleblower Center
  • Whistleblower Handbook
Whistleblower Network News

Whistleblower Network News is an independent online newspaper providing our readers with up-to-date information on whistleblowing. Our goal is to be the best source of information on important qui tam, anti-corruption, compliance, and whistleblower law developments. 

Submit an Article
  • ABOUT
  • ADVERTISE
  • PRIVACY POLICY
  • TERMS OF USE
  • CAREERS
  • CONTACT

Copyright © 2020, Whistleblower Network News. All Rights Reserved.

This Newspaper/Web Site is made available by the lawyer or law firm publisher for educational purposes only as well as to give you general information and a general understanding of the law, not to provide specific legal advice. By using this website, you understand that there is no attorney-client relationship between you and the Newspaper/Web Site publisher. The Newspaper/Web Site should not be used as a substitute for competent legal advice from a licensed professional attorney in your state.

No Result
View All Result
  • Home
  • News
    • Corporate
    • Dodd-Frank
    • False Claims-Qui Tam
    • Foreign Corruption
    • Government
    • Intelligence
    • IRS & Tax
    • Legislation
    • OSHA
    • Sarbanes-Oxley
    • SEC
  • Editorial
  • Opinion
  • Whistleblower of the Week
  • Login

Copyright © 2020, Whistleblower Network News. All Rights Reserved.

Welcome Back!

Sign In with Facebook
Sign In with Google
OR

Login to your account below

Forgotten Password?

Create New Account!

Sign Up with Facebook
Sign Up with Google
OR

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In
Go to mobile version